Rifasutenizol

Rifasutenizol (TNP-2198) is a dual-targeted antibacterial agent that has a good antibacterial effect on Helicobacter pylori infection. Rifasutenizol can be used in the study of microaerophilic and anaerobic bacterial infections[1].

Product Specifications

CAS Number

[1001314-13-1]

Product Name Alternative

TNP-2198

UNSPSC

12352005

Target

Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/rifasutenizol.html

Purity

99.53

Solubility

10 mM in DMSO

Smiles

O=C(C)O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(C(NC(C(C2=C3C4=C(O[C@](C)(O/C=C/[C@H](OC)[C@H]1C)C4=O)C(C)=C2O)=O)=C5C3=NC6(CCN(CCN7C([N+]([O-])=O)=CN=C7C)CC6)N5)=O)/C

Molecular Formula

C48H61N7O13

Molecular Weight

944.04

References & Citations

[1]Ma Z, et al. Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens. J Med Chem. 2022;65 (6) :4481-4495. |[2]Li X, et al. Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials[J]. The Lancet Infectious Diseases, 2024, 24 (6) : 650-664.